You Position: Home > Paper
氟喹诺酮类药物在耐药结核病中应用的再评价
( views:253, downloads:580 )
- Author:
- No author available
- Journal Title:
- Chinese Journal of Tuberculosis and Respiratory Diseases
- Issue:
- 10
- DOI:
- 10.3760/cma.j.issn.1001-0939.2014.10.004
- Key Word:
- No keyword available
Abstract： 自利福平问世以来的近50年间,抗结核新药的研发不尽如人意,不能满足日益增加的耐药结核病治疗的需要.氟喹诺酮类药物在耐药结核病,尤其是耐多药结核病(MDR-TB)治疗中的作用弥补了抗结核新药开发的不足,为耐药结核病的治疗做出了一定的贡献[1-4].但随着耐药MTB的变迁,氟喹诺酮类药物在耐药结核病中的应用受到了较大的挑战,如何更好地评价和合理使用氟喹诺酮类药物是临床医生所期待回答的问题.
- [1]陆宇,朱莉贞,段连山.左氧氟沙星的抗结核作用研究[J].2000,(1).
- [2]主编肖和平.耐药结核病化学治疗指南:2010年[M].2011.
- [3]Rodriguez JC,Garcia Pachon E,Cremades R,etc.Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.[J].2011,66(10).
- [4]唐神结.耐药结核病防治手册[M].1900.
- [5]Takiff H,Guerrero E.Current prospects for the fluoroquinolones as first-line tuberculosis therapy.[J].2011,55(12).
- [6]Sun H,Gu J,Yao L,etc.Extensively drug-resistant tuberculosis at a tuberculosis specialist hospital in Shanghai, China: clinical characteristics and treatment outcomes.[J].2011,43(4).
- [7]Jun, Chen,Zhifei, Chen,Yuanyuan, Li,etc.Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China.[J].1900,16(2).
- [8]Fouad M,Gallagher JC.Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis.[J].2011,45(11).
- [9].A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system[J].2012,67(4).
- [10]主编唐神结.结核病临床诊治进展年度报告[M].2012.
- [11]Jinwoo, Lee,Chang-Hoon, Lee,Deog Kyeom, Kim,etc.Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.[J].2011,26.
- [12]Leimane, V.,Riekstina, V.,Chen, M. P.,etc.Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004[J].2010,36(3).
- [13]Jo,K.-W.,Lee,S.-D.,Kim,W.S.,etc.Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis[J].2014,18(1).
- [14]Coates AR,Mitchison DA,Hu Y.Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis.[J].2003,47(2).
- [15]Marra F,Elwood KR,Moadebi S,etc.Fluoroquinolones for the treatment of pulmonary tuberculosis.[J].2007,67(14).
- [16]L E, Ziganshina,S B, Squire.Fluoroquinolones for treating tuberculosis.[J].2008,(1).
- [17]Veziris N,Poissy J,Aubry A,etc.Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.[J].2010,54(11).
- [18]Ahmad,Z.,Tyagi,S.,Minkowski,A.,etc.Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis[J].2013,188(1).
- [19]Devasia,R.,Sterling,T.R.,Tang,Y.-W.,etc.High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility[J].2012,50(4).
- [20]Jacobson KR,Tierney DB,Jeon CY,etc.Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis.[J].2010,51(1).
- [21]Warkentin, J.V.,Sterling, T.R.,Eden, S.,etc.Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones[J].2013,42(3).
- [22]Koh,W.-J.,Lee,S.H.,Kang,Y.A.,etc.Comparison of levofloxacin versusmoxifloxacin for multidrug-resistant tuberculosis[J].2013,188(7).
- [23]Kliiman K,Altraja A.Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB.[J].2009,33(5).